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Background-—Clinical characteristics and outcomes of takotsubo syndrome (TTS) patients with malignancy have not been fully
elucidated. This study sought to explore differences in clinical characteristics and to investigate short- and long-term outcomes in
TTS patients with or without malignancy.
Methods and Results-—TTS patients were enrolled from the International Takotsubo Registry. The TTS cohort was divided into
patients with andwithout malignancy to investigate differences in clinical characteristics and to assess short- and long-termmortality.
A subanalysis was performed comparing long-term mortality between a subset of TTS patients with or without malignancy and acute
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T akotsubo syndrome (TTS) represents an acute heartfailure condition, which can occur in the setting of severe psychological or physical stress.
1,2 While multiple
theories have been postulated to explain the pathophysiology
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of TTS, the exact mechanism of this entity remains uncertain.3–5
Thus far, several case reports have described the occurrence of
TTS in the setting of malignancy and chemotherapy administra-
tion.6,7 However, it remains unclear what role malignancy or
chemotherapy play in the development in TTS with regard to
physical and emotional stress.8 It has been suggested that
treatment of malignancy rather than malignancy itself is associ-
ated with the development of TTS.9 In recent publications
using data from the International Takotsubo Registry (InterTAK
Registry, www.takotsubo-registry.com), we found that outcomes
ofTTSintheacutesettingcarryhighmorbidityandmortalitysimilar
to that found in acute coronary syndrome (ACS).10,11 This poses a
challenging clinical scenario where the clinical course could
potentially be affected by the triple hit of malignancy, treatment,
anddevelopmentof TTS. Enhancingour understandingof TTSas it
pertains tomalignancymay aid in improving our understanding of
the diagnostic workup for potential triggers of TTS, particularly
those associatedwith aworseoutcome. There is only limited data
on the impact ofmalignancy on clinical outcomes of patients with
TTS. Small scale studies have reported that malignancy might
affect long-termoutcomesofTTS.12,13Thus, theaimof thepresent
study was to explore differences in clinical characteristics and to
investigate both short- and long-term outcomes in TTS patients
with or without malignancy and to compare these outcomes to
patients with ACS with or without malignancy.
Methods
Study Design
The InterTAK Registry is a multicenter collaboration com-
prised of 26 cardiovascular centers from 9 different countries
(Austria, Finland, France, Germany, Italy, Poland, Switzerland,
the United Kingdom, and United States). Data collected are
observational and in part retrospective as well as prospective.
The authors declare that all supporting data are available
within the article. A detailed description of the rationale,
design, and objectives of the InterTAK Registry has recently
been published elsewhere.14 Diagnosis of TTS was based on
modiﬁed Mayo Clinic Diagnostic Criteria.10,15 Patients with
evidence of myocarditis were excluded from the study.
Additionally, the Zurich Acute Coronary Syndrome Registry,10
a single center database of ACS patients was used to
compare TTS patients from the InterTAK Registry to age- and
sex-matched ACS patients. From these study populations
patients were selected in whom information on malignancy
was available. The study protocol was reviewed by the
respective local ethics committees or investigational review
boards at each collaboration site. Due to the partly retro-
spective nature of the study, ethics committees of most study
centers waived the need for informed consent. At centers in
which the ethics committees or investigational review boards
required informed consent or in which patients were included
prospectively, formal written consent was obtained from
patients or surrogates.
Study Population and Data Collection
Of 1750 TTS patients in the InterTAK Registry, 1604 patients
in whom comprehensive data on malignancy were available
were included in the present analysis (Figure 1). Patients were
categorized into 2 groups based on the presence or absence
of malignancy documentation.
For a subanalysis we included 455 TTS patients and 455
age- and sex-matched ACS patients and selected those with
available information on malignancy (n=411 for TTS patients
and n=441 for ACS patients, Figure 1). TTS patients for the
matching study were included from the University Hospital
Zurich, Kantonsspital Lucerne, University Hospital Basel,
Mayo Clinic Rochester, and Heidelberg University Hospital,
as previously described.10
Characteristics for the comparison of TTS patients with
and without malignancy included demographics, precipitating
factors, cardiovascular risk factors, comorbidities, medication
on admission and at discharge, laboratory values, electrocar-
diographic, echocardiographic, and cardiac catheterization
data. Outcome data for TTS and ACS were obtained from
hospital visits, medical charts, or telephone interviews.
Analyses were performed within the TTS group as well as in
comparison with the ACS group. In the ﬁrst analysis, the TTS
cohort was subdivided into patients with and without
malignancy to investigate differences in patients’ character-
istics and to assess short- and long-term mortality. A separate
analysis was performed comparing a subset of TTS patients
Clinical Perspective
What Is New?
• A substantial number of takotsubo syndrome (TTS) patients
show an association with malignancy.
• The prevalence of malignancies in TTS is higher than in
acute coronary syndrome.
• TTS patients with malignancies have a different clinical
proﬁle including an older age at time of TTS onset and a
higher prevalence of physical triggering factors.
What Are the Clinical Implications?
• The ﬁndings of the present study suggest that speciﬁc
malignancy-related factors might be associated with the
development of TTS.
• Further research is required to investigate the interplay of
malignancy and TTS, which might be helpful to elucidate the
pathophysiological mechanism of TTS.
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with ACS to delineate the prevalence of malignancy and long-
term mortality (Figure 1).
Statistical Analyses
Descriptive statistics are given as counts with percentages for
categorical variables and as meanstandard deviation or
median with interquartile range (IQR) for continuous variables.
Categorical variables were analyzed by using the Pearson
Chi-Square or Fisher exact test, if indicated. Student t test
or Mann–Whitney U test were executed for continuous
variables. Kaplan–Meier survival analysis was used to assess
short- and long-term mortality and the log-rank test was
applied for group comparison.
A multivariable Cox-regression for long-term mortality
was performed with covariates, which were statistically
signiﬁcant in the univariable analysis. Factors controlled
for in the multivariable analysis included: age >70 years,
female sex, emotional trigger, physical trigger, chest pain
on admission, atrial ﬁbrillation, heart rate >70 bpm,
systolic blood pressure >130 mm Hg, maximum troponin
>10 times upper limit of the normal (ULN), maximum
creatine kinase >10 times ULN, C-reactive protein maxi-
mum, white blood cell count maximum, left ventricular
ejection fraction (LVEF) <45%, malignancy, coronary artery
disease, neurologic disorders, and psychiatric disorders.
Data of covariates were 89.9% complete. Missing data
were completed with multiple imputations before multi-
variable Cox-regression. To address clustering within
countries, we repeated the Cox-regression with cluster
robust standard errors adjusted for 9 countries. A 2-sided
P<0.05 was deﬁned as statistical signiﬁcance. IBM SPSS
Statistics, version 22.0 and 23.0 (Armonk, NY: IBM Corp)
and Stata software, version 13.1 (StataCorp) were used for
statistical analyses. Figures were compiled with Prism 7.00
(GraphPad, La Jolla, CA).
Results
Study Population
Of the total 1604 TTS patients in the InterTAK Registry,
malignancy was observed in 267 (16.6%) (Figure 1 and
Figure 2, left column).10 The most frequent type of malig-
nancy was breast cancer 26.2% (n=70), followed by tumors
affecting the gastrointestinal system 16.1% (n=43), respira-
tory tract 15.4% (n=41), internal sex organs 14.6% (n=39),
skin 13.1% (n=35), lymphatic system 7.1% (n=19), endocrine
organs 6.7% (n=18), urinary tract 5.2% (n=14), and hemato-
logic 3.0% (n=8) as well as the central nervous system 2.2%
(n=6). In the subgroups, the overall prevalence of malignancy
was 18.2% in the TTS cohort and 11.1% in the ACS cohort
(Figure 2, middle and right column).
Patients’ Characteristics
On admission, TTS patients with malignancy were older
compared with those without malignancy (69.511.2 years
versus 65.813.1 years, P<0.001), while no sex differences
were observed (87.6% versus 89.8% women, P=0.29). TTS
1750 Patients from the InterTAK Registry were assessed for eligibility Zurich ACS Registry
1337 Without Malignancies 267 With Malignancies
455 Patients from each group 
matched for age and sex
411 TTS Patients with complete 
information on malignancies
441 ACS Patients with complete 
information on malignancies
Outcome AnalysisPredictors of mortalityOutcomesClinical Profile
146 With missing 
information on 
malignancies were 
excluded 
Figure 1. Study ﬂowchart. Flowchart summarizes patients’ selection and respective analyses of the study. ACS indicates acute coronary
syndrome; TTS, takotsubo syndrome.
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patients with malignancy on initial presentation experienced
chest pain less frequently (67.8% versus 77.5%, P<0.001), but
had dyspnea more often (53.5% versus 45.8%, P=0.029)
(Table 1). Emotional stressors were less common in patients
with malignancy compared with those without (18.0% versus
30.3%, P<0.001). In contrast, physical triggering factors were
more often observed in TTS patients with malignancy than in
those without malignancy (47.9% versus 34.2%, P<0.001). Of
these, a substantial proportion of TTS patients with malig-
nancy developed a TTS episode after a medical intervention or
physical trauma (12.7% versus 5.5%, P<0.001 Table 2). No
differences were observed with regard to admission systolic
and diastolic blood pressure measurements between the 2
groups. Of note, LVEF was lower in TTS patients with
malignancy than in TTS patients without malignancy
(38.8%11.8% versus 41.5%11.9%, P=0.001), with no
differences in left ventricular end-diastolic pressure
(21.58.1 mm Hg versus 21.58.0 mm Hg, P=0.97). Car-
diac biomarkers on admission and their peak values did not
signiﬁcantly differ between TTS patients with or without
malignancy (Table 1). TTS patients with malignancy had
higher levels of C-reactive protein on admission (6.50 mg/
L, IQR 2.00–26.08 versus 3.56 mg/L, IQR 1.30–10.13,
P<0.001) as well as peak levels during hospitalization
(17.00 mg/L, IQR 4.90–71.60 versus 7.85 mg/L, IQR 2.56–
33.00, P<0.001) compared with TTS patients without malig-
nancy. White blood cell count showed no differences between
the 2 groups (Table 1). Prevalence of preexisting cardiovas-
cular risk factors was comparable between TTS patients with
and without malignancy. TTS patients with malignancy tended
to have an acute or chronic neurologic disorder more often
(29.5% versus 23.5%, P=0.047).
Outcomes
TTS patients with malignancy required acute cardiac care
treatment more frequently (26.7% versus 19.4%, P=0.007),
predominantly due to greater need for invasive or non-
invasive respiratory support (23.7% versus 15.7%, P=0.002)
and had a higher in-hospital mortality (6.7% versus 3.4%,
Figure 2. Prevalence of malignancy. Prevalence of malignancy in the total study cohort of TTS patients
(left column), subcohort of TTS (middle column) and ACS (right column) shows an increased prevalence of
malignancy in TTS when compared with ACS.10 If a patient had a history of >1 malignancy then the patient
was categorized into all respective groups of malignancies. ACS indicates acute coronary syndrome; TTS,
takotsubo syndrome.
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Table 1. Characteristics of Patients With and Without Malignancy
Characteristics
TTS with Malignancy TTS w/o Malignancy
P Valuen=267 n=1337
Demographics
Female sex 234/267 (87.6) 1201/1337 (89.8) 0.29
Age, y 69.511.2 (n=267) 65.813.1 (n=1337) <0.001
Body mass index, kg/m2 25.35.6 (n=206) 25.15.4 (n=1031) 0.59
Triggers
Physical trigger 128/267 (47.9) 457/1337 (34.2) <0.001
Emotional trigger 48/267 (18.0) 405/1337 (30.3) <0.001
Both emotional and physical trigger 26/267 (9.7) 99/1337 (7.4) 0.19
No evident trigger 65/267 (24.3) 376/1337 (28.1) 0.21
TTS type
Apical type 222/267 (83.1) 1079/1337 (80.7) 0.35
Symptoms on admission
Chest pain 166/245 (67.8) 969/1250 (77.5) 0.001
Dyspnea 131/245 (53.5) 574/1252 (45.8) 0.029
Cardiac biomarkers
Troponin on admission—factor increase in ULN * 7.50 (1.98–28.70) n=221 7.50 (2.36–22.00) n=1094 0.75
Troponin maximum—factor increase in ULN * 15.00 (4.34–50.13) n=226 12.55 (4.53–37.19) n=1104 0.49
Creatine kinase on admission—factor increase in ULN 0.81 (0.48–1.36) n=175 0.88 (0.54–1.50) n=925 0.11
Creatine kinase maximum—factor increase in ULN 1.14 (0.58–1.91) n=186 1.10 (0.64–2.17) n=938 0.49
BNP on admission—factor increase in ULN† 8.30 (3.55–18.86) n=66 5.52 (2.00–15.19) n=343 0.06
BNP maximum—factor increase in ULN† 12.60 (5.44–24.38) n=87 9.39 (3.73–22.91) n=449 0.11
Inflammatory markers
CRP on admission, mg/L 6.50 (2.00–26.08) n=152 3.56 (1.30–10.13) n=898 <0.001
CRP maximum, mg/L 17.00 (4.90–71.60) n=167 7.85 (2.56–33.00) n=944 <0.001
WBC on admission, 103/lL 9.70 (7.19–12.70) n=229 9.72 (7.54–12.80) n=1141 0.48
WBC maximum, 103/lL 10.70 (7.52–13.80) n=235 10.50 (8.20–13.62) n=1158 0.77
ECG on admission
Atrial fibrillation 17/244 (7.0) 82/1215 (6.7) 0.90
ST-segment elevation 100/243 (41.2) 532/1212 (43.9) 0.43
T-wave inversion 94/243 (38.7) 510/1212 (42.1) 0.33
QTc, ms 456.050.5 (n=193) 457.949.5 (n=893) 0.64
Hemodynamics
Heart rate, beats/min 90.823.0 (n=222) 86.821.8 (n=1117) 0.012
Systolic blood pressure, mm Hg 133.830.1 (n=224) 130.328.5 (n=1116) 0.10
Diastolic blood pressure, mm Hg 77.918.0 (n=223) 76.816.9 (n=1069) 0.36
Left ventricular ejection fraction, %‡ 38.811.8 (n=250) 41.511.9 (n=1221) 0.001
Left ventricular end-diastolic pressure, mm Hg 21.58.1 (n=160) 21.58.0 (n=801) 0.97
Cardiovascular risk factors/history
Hypertension 176/262 (67.2) 867/1328 (65.3) 0.56
Diabetes mellitus 42/263 (16.0) 194/1330 (14.6) 0.56
Current smoking 44/258 (17.1) 274/1290 (21.2) 0.13
Continued
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P=0.010). While 30-day mortality did not differ between TTS
patients with and without malignancy (P=0.17; Figure 3,
inset), long-term survival analyses showed a higher mortality
in TTS patients with malignancy (P<0.001; Figure 3). During
the 5-year follow-up period, 47 patients with malignancies
and 109 patients without malignancies deceased. In these
156 patients, the cause of death was known in 151 (96.7%)
patients. 20 (46.5%) cardiovascular deaths and 23 (53.5%)
non-cardiovascular deaths were observed in the malignancy
group, while there were 77 (71.3%) cardiovascular deaths
and 31 (28.7%) non-cardiovascular deaths in the non-
malignancy group. Interestingly, a subgroup survival analysis
of TTS patients compared with ACS patients according to
presence or absence of malignancy revealed that TTS
patients with malignancy had a comparable long-term
outcome with ACS patients with malignancy (P=0.13,
Figure 4) and TTS patients without malignancy also showed
a comparable outcome with ACS patients without malig-
nancy (P=0.54, Figure 4).
Results of multivariable analysis in the entire cohort of
1604 TTS patients demonstrated that age >70 years, atrial
ﬁbrillation, peak troponin >10x ULN, peak creatinine
kinase >10x ULN, LVEF <45%, malignancy, neurologic
conditions, and psychiatric disorders were independent
Table 1. Continued
Characteristics
TTS with Malignancy TTS w/o Malignancy
P Valuen=267 n=1337
Hypercholesterolemia 77/262 (29.4) 421/1325 (31.8) 0.45
Coexisting medical condition
Coronary artery disease§ 34/237 (14.3) 193/1232 (15.7) 0.61
COPD or asthma 56/260 (21.5) 203/1332 (15.2) 0.012
Neurologic disorders (total)k 74/251 (29.5) 278/1181 (23.5) 0.047
Psychiatric disorders (total)k 89/251 (35.5) 376/1181 (31.8) 0.27
Medication on admission
ACE inhibitor or ARB 77/215 (35.8) 422/1088 (38.8) 0.41
Beta-blocker 79/215 (36.7) 344/1088 (31.6) 0.14
Calcium-channel antagonist 21/209 (10.0) 72/1080 (6.7) 0.08
Statin 37/209 (17.7) 196/1080 (18.1) 0.89
Medication at discharge
ACE inhibitor or ARB 180/234 (76.9) 978/1218 (80.3) 0.24
Beta-blocker 188/234 (80.3) 945/1218 (77.6) 0.35
Calcium-channel antagonist 26/234 (11.1) 98/1218 (8.0) 0.12
Statin 109/234 (46.6) 644/1218 (52.9) 0.08
In-hospital complications
Cardiogenic shock 31/266 (11.7) 125/1328 (9.4) 0.26
Death 18/267 (6.7) 45/1337 (3.4) 0.010
Acute cardiac care treatment 71/266 (26.7) 258/1333 (19.4) 0.007
Intra-aortic balloon pump 8/266 (3.0) 34/1333 (2.6) 0.67
Invasive or noninvasive ventilation 63/266 (23.7) 209/1333 (15.7) 0.002
Cardiopulmonary resuscitation 26/266 (9.8) 110/1333 (8.3) 0.42
Catecholamine use 40/266 (15.0) 151/1333 (11.3) 0.09
Values are meanSD, no./total n (%), or median (interquartile range). ACE indicates angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker; BNP, brain natriuretic peptide;
COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ECG, electrocardiogram; QTc, QT interval corrected for heart rate; TTS, takotsubo syndrome; ULN, upper limit of the
normal; WBC, white blood cell count.
*Including upper limits of the normal range for troponin T, high-sensitivity troponin T, and troponin I.
†Including upper limits of the normal range for brain natriuretic peptide and the N-terminal of prohormone brain natriuretic peptide.
‡Data obtained during catheterization or echocardiography if both results were available data from catheterization were used.
§Coexisting coronary artery disease during acute hospitalization.
kCategory includes patients with either an acute as well as past or chronic disorder.
DOI: 10.1161/JAHA.118.010881 Journal of the American Heart Association 6
Malignancy in Takotsubo Syndrome Cammann et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on August 9, 2019
predictors of long-term mortality (Figure 5). Results
remained similar when assessing clustering among coun-
tries (Figure S1).
Discussion
Leveraging on the largest database of TTS patients published
thus far, we have provided a more detailed analysis of
prevalence and outcome of patients with malignancy and TTS.
Here we show that TTS and ACS patients with malignancies
have comparable long-term outcomes. Furthermore, we found
that in TTS patients with malignancy, the inciting event is an
emotional trigger less frequently than in those without malig-
nancy. Even though the psychological burden of a malignancy
diagnosis could potentially increase sympathetic output, this
was not the case in our analysis as emotional stressors were
less common in patients with malignancy compared with those
without. It is noteworthy that the prevalence of psychiatric
disorders including anxiety and depression was not signiﬁcantly
different in TTS patients with malignancy compared to without
malignancy. With regard to inﬂammatory markers, while the
total number of white blood cell counts were not different
between the groups, C-reactive protein levels were signiﬁcantly
higher in the TTS patients with malignancy in those without
malignancy, likely a marker of the greater comorbidity burden.
While multiple theories have been postulated to explain the
pathophysiology of TTS, the exact mechanisms of this acute
transient decrease in left ventricular function remain uncer-
tain.1,4,5 The relationship between malignancy and TTS is
particularly interesting from an epidemiologic, mechanistic,
and outcome standpoint as malignancy and chemotherapy
Table 2. Triggering Factors of TTS Patients
TTS with
Malignancy
TTS w/o
Malignancy P Value
Physical triggering factors
Acute respiratory failure 6.5% 7.6% 0.47
Central nervous
system conditions
7.5% 5.1% 0.12
Malignancy 3.0% 0% <0.001
Infection 5.2% 2.5% 0.014
Post surgery/physical trauma 12.7% 5.5% <0.001
Others 13.1% 13.5% 0.85
Emotional triggering factors
Anger/frustration 1.9% 4.7% 0.036
Related to financial or
employement problems
0% 2.5% 0.008
Grief/loss 4.1% 6.9% 0.09
Interpersonal conflict 3.0% 4.8% 0.20
Panic/fear/anxiety 4.9% 6.7% 0.27
Others 4.1% 4.7% 0.67
TTS indicates takotsubo syndrome.
Figure 3. Short- and long-term outcome in takotsubo patients with and without
malignancy. Kaplan–Meier survival analysis demonstrated a comparable 30-day survival
of TTS patients with and without malignancy (P=0.17, inset), while long-term mortality was
signiﬁcantly higher in TTS patients with malignancy than in TTS patients without malignancy
(P<0.001). TTS indicates takotsubo syndrome.
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have been associated with TTS.9,12,16–19 Endothelial dysfunc-
tion in epicardial and microvascular coronary arteries occurs
frequently in patients with cancer,20 especially during and after
systemic chemotherapy or radiotherapy of the heart region,
which might be a predisposing factor for developing TTS.
Therefore, assessment of endothelial function, such as acetyl-
choline spasm provocation testing, would probably be useful in
further deﬁning mechanisms in this patient population. Inter-
estingly, the prevalence of malignancy in our TTS cohort
exceeded the reported rates of the general population in
Europe21 when stratiﬁed according to age and sex (female: 0–
44 years [8.3% versus 0.4%], 45–64 years [12.8% versus
3.7%], >65 years [18.9% versus 7.9%]; male: 0–44 years [5.2%
versus 0.3%], 45–64 years [21.9% versus 1.91%], >65 years
[20.8% versus 7.8%]). Another investigation reported that
underlying cardiac comorbidities were independent predictors
of long-term mortality in patients with TTS.22 Also in this
cohort, malignancy was more common in those patients who
did not survive long-term. This is of particular interest since
data from our registry further reveal a strong association
between TTS and malignancy. Moreover, in a recent publication
using data from the InterTAK Registry, we demonstrated that
outcomes of TTS in the acute setting carry a high morbidity and
mortality similar to ACS and that the prevalence of malignancy
in TTS exceeds that of ACS.10,23 This poses a challenging
clinical scenario in the management of patients with
malignancy. Not only does TTS carry a high rate of mortality
similar to that of ACS,10 its concomitant diagnoses in
malignancy patients may pose worse outcomes. As there are
no standardized guidelines regarding screening or risk strat-
iﬁcation for TTS in patients with malignancy, understanding
potential underlying causes and the clinical importance of the
association of TTS and malignancy may help improve clinical
outcomes. As such, it is reasonable to consider malignancy as
a potential triggering factor of TTS. Additionally, in certain
patients TTS may be considered a paraneoplastic syndrome, a
harbinger for the presence of underlying malignancy. Alterna-
tively, metabolic and/or neurohumoral changes associated
with malignancy may increase the likelihood of a TTS episode.
Even if the relationship between developing TTS and malig-
nancy cannot be deemed causative, screening for malignancy
in those with acute episodes of TTS can perhaps prompt further
therapy and improve overall outcomes.24
The numerous effects of malignancy and therapies on the
heart are evidenced by the rapid evolution of the ﬁeld of cardio-
oncology. As such the malignancy patient subset of TTS
provides a unique milieu to investigate possible etiologic
factors of the interaction between the 2 disease entities and
their treatment. Furthermore, studies focusing on the time-
relationship of cancer therapies, such as chemotherapy,
immunotherapy, and radiation treatment, and onset of TTS is
essential to elucidate the relationship between TTS and cancer.
Figure 4. Long-term outcome in takotsubo syndrome and acute coronary syndrome according to
presence or absence of malignancy. Kaplan–Meier survival analysis showed that patients with malignancy
had signiﬁcantly worse outcome than those without malignancy both in patients with TTS and ACS. In
addition, TTS patients with malignancy had a comparable long-term outcome with ACS patients with
malignancy (P=0.13) and TTS patients without malignancy also showed a comparable outcome with ACS
patients without malignancy (P=0.54). ACS indicates acute coronary syndrome; TTS, takotsubo syndrome.
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Limitations
To study the relationship between TTS and cancer is
challenging as questions remain as to whether the worse
prognosis is related to the presence and speciﬁc type, stage,
and treatment for malignancy, the presence of TTS, or a
combination of these factors. In addition, the different type
and stage of cancer might affect the outcome, however, the
Figure 5. Univariable (A) and multivariable (B) predictors of long-term mortality in takotsubo syndrome.
Results of themultivariable Cox-regression in the total cohort of TTS patients showed that age>70 years, atrial
ﬁbrillation, maximum troponin >10x ULN, maximum creatinine kinase >10x ULN, left ventricular ejection
fraction<45%,malignancy, neurologic disorders, and psychiatric disorders are independent predictors of long-
term mortality. Error bars represent 95% CI. Black rhombi indicate statistical signiﬁcance; grey rhombi not
statistically signiﬁcant. CI indicates conﬁdence interval; HR, hazard ratio; ULN, upper limit of the normal range.
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number of patients with certain type or stage of cancer is too
small for a meaningful comparison analysis in our cohort.
Conclusions
The ﬁndings of the present study have unraveled a high
prevalence of malignancy in TTS patients. Additionally, our
analyses illustrate the clinical course and unique character-
istics in TTS patients with or without malignancy as compared
to a cohort of ACS patients. Our ﬁndings suggest that speciﬁc
malignancy-associated factors impact the development and
outcome of TTS. Therefore, to fully understand the patho-
physiology of TTS and the role of malignancy in triggering or
affecting outcomes, this subset of patients deserves further
investigation. These factors may include analysis of speciﬁc
malignancy types and metabolic and neurohumoral changes
associated with it and/or the effects of distinct therapeutic
molecules administered in such patients. Therefore, develop-
ing speciﬁc quantiﬁable metrics relevant to this unique patient
population to improve outcomes is warranted.
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Figure S1. Cox-regression for long-term mortality with cluster robust standard 
errors adjusted for 9 countries. 
 
 
 
 
 
Cox-regression with cluster robust standard errors adjusting for the nine participating 
countries revealed similar results as that without clustering.  
Black, statistically significant predictors; grey, not significant.  
CI, confidence interval; HR, hazard ratio; ULN, upper limit of the normal range. 
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